Neurofilament Light Chain
Neurofilaments are cytoskeletal proteins expressed in neurons, especially within large myelinated axons, where they provide structural support and regulate axonal diameter, thereby influencing nerve conduction velocity. They are composed of three major subunits: light chain (NFL), medium chain (NFM), and heavy chain (NFH). Of these, NFL is the most abundant and most readily released into extracellular fluids following axonal injury. Due to this reason, NFL quantitation in the blood is used as a marker of neuronal integrity and its levels correlate with the extent of progressive neurological disorders in Alzheimer’s and Parkinson’s disease.
In Alzheimer’s, the levels of NFLs in blood has been correlated with the extent of cognitive decline. In Parkinson’s, the levels reflect the stages of the disease. Apart from these two conditions, NFL levels have also been shown to significantly elevate in amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), dementia, and traumatic brain injury (due to neuronal stress and injury). Several clinical trials have shown that NFL levels can be used as an early diagnosis and prognostic marker in these neurodegenerative and demyelinating diseases. However, it should be noted that a higher quantity of NFLs are released in the cerebrospinal fluid (CSF) and the blood levels of NFL are approximately 40-fold lower than in CSF but can be detected with ultrasensitive immunoassays. Serum values are typically 5–10% higher than plasma. Considering the progressive age-associated neuronal decline, NFL levels decline by 2-3% per year in all individuals, irrespective of any existing neurological disorder.
- Early detection and prognostication of neurodegenerative and demyelinating diseases
- Monitoring disease progression and therapeutic response (e.g., MS, ALS, Alzheimer’s disease)
- Risk stratification and assessment of cognitive decline in Alzheimer’s and related dementias
Increased in:
- Alzheimer’s disease (correlates with cognitive decline severity)
- Parkinson’s disease (associated with disease stage)
- Amyotrophic lateral sclerosis (strong elevations, correlate with prognosis)
- Multiple sclerosis (active disease and progression)
- Frontotemporal dementia
- Traumatic brain injury (reflects neuronal injury severity)
Limitations: NFL elevation is not specific to a single disorder. Results should be interpreted alongside clinical findings, imaging, and complementary biomarkers. Acute neuronal injury (e.g., stroke, trauma) can also raise levels.
| Age Range | Reference Value (pg/mL) |
|---|---|
| < 2.5 years | ≤ 12.8 |
| 2.5 – 4 years | ≤ 11.8 |
| 5 – 9 years | ≤ 10.4 |
| 10 – 14 years | ≤ 8.8 |
| 15 – 19 years | ≤ 9.2 |
| 20 – 24 years | ≤ 10.4 |
| 25 – 29 years | ≤ 11.9 |
| 30 – 34 years | ≤ 13.5 |
| 35 – 39 years | ≤ 15.3 |
| 40 – 44 years | ≤ 17.3 |
| 45 – 49 years | ≤ 19.7 |
| 50 – 54 years | ≤ 22.4 |
| 55 – 59 years | ≤ 25.4 |
| 60 – 64 years | ≤ 28.8 |
| 65 – 69 years | ≤ 32.7 |
| 70 – 74 years | ≤ 37.1 |
| 75 – 79 years | ≤ 42.1 |
| 80 – 84 years | ≤ 47.8 |
| ≥ 85 years | ≤ 54.3 |
EDTA plasma or serum; cerebrospinal fluid.
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Frozen: 90 days (at -20°C or lower)
- Clin Chim Acta. 2026 Jan 1;578:120580. [PMID: 40889674]
- Int J Mol Sci. 2023 Jul 19;24(14):11624. [PMID: 37511382]
- Neurosci Biobehav Rev. 2019 Jul;102:123-138. [PMID: 31026486]
- Expert Rev Mol Diagn. 2025 Aug;25(8):419-424. [PMID: 40392201]
- BMJ Med. 2025 Jan 11;4(1):e000958. [PMID: 39845125]
- J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881. [PMID: 30967444]
- Clin Chem Lab Med. 2023 Oct 27;62(4):698-705. [PMID: 37882772]
- Front Aging Neurosci. 2025 Jan 20;17:1517663. [PMID: 39906713]